Glucocorticoids have been the treatment mainstay for giant cell arteritis (GCA) for several decades (1). Current guidelines recommend glucocorticoids as an induction therapy, and they also clearly outline tapering schemes and options for flare management. Methotrexate can be used as a glucocorticoid-sparing strategy, but this approach is not supported by strong evidence (2-5). In 2017, the Giant Cell Arteritis Clinical Research Study (GiACTA) provided strong evidence for a good risk/benefit ratio of tocilizumab in GCA (6). Based on the results of GiACTA, which included 251 patients, the US Food and Drug Administration and the European Medicines Agency approved this drug for the treatment of GCA. Several recent and ongoing trials with biologics or JAK inhibitors (JAKi) offer even more promise of further optimizing GCA therapy. These developments include the use of mavrilimumab (an IgG4 humanized monoclonal antibody blocking the granulocyte–macrophage colony-stimulating factor receptor α), ustekinumab (an interleukin-12/23 inhibitor), and the JAKi baricitinib. A recently published proof-of-concept study demonstrated that baricitinib at 4 mg/day permitted discontinuation of glucocorticoids in most patients with relapsing GCA. Specifically, 13 of the 14 patients who completed 52 weeks not only achieved disease remission but also discontinued glucocorticoids